icon-folder.gif   Conference Reports for NATAP  
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 3 in clinical practice - Results from the GErman hepatitis C COhort (GECCO)
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Patrick Ingiliz1, Knud Schewe2, Thomas Lutz3, Christoph Boesecke4, Stefan Mauss5, Heiner Busch6, Axel Baumgarten1, Marcel Schuetze1, Torben Kimhofer7, Guenther Schmutz5, Stefan Christensen6, Karl Georg Simon8, Dietrich Hueppe9 1Center for Infectiology, Berlin,2 Infektionsmedizinisches Centrum Hamburg, Hamburg,3Infektiologikum, Frankfurt, 4Medical Department 1, University Hospital Bonn, 5Center for HIV and Hepatogastroenterology, Duesseldorf, 6CIM Infectious diseases, Muenster,
7Division of Computational and Systems Medicine, Department of Surgery and Cancer, FoM, Imperial College London, London, UK, 8 Practice for Gastroenterology Leverkusen, Leverkusen, Germany, 3 Practice for Gastroenterology Herne, Herne, Germany.
EACS: Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - Results from the German hepatitis C cohort (GECCO) (10/27/15)